Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate efficacy and safety of Dovitinib(TKI258) in patients
with castration resistant prostate cancer after failure of docetaxel-based chemotherapy.
Further correlative study for metabolic response using PET image and change in serum
fibroblast growth factor 23(FGF23) will be conducted.